Cargando…
Management of Retinitis Pigmentosa Via Wharton’s Jelly-Derived Mesenchymal Stem Cells or Combination With Magnovision: 3-Year Prospective Results
To investigate whether the natural progression rate of retinitis pigmentosa (RP) can be decreased with subtenon Wharton’s jelly-derived mesenchymal stem cell (WJ-MSC) application alone or combination with Magnovision. The study included prospective analysis of 130 eyes of 80 retinitis pigmentosa pat...
Autores principales: | Ozmert, Emin, Arslan, Umut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552690/ https://www.ncbi.nlm.nih.gov/pubmed/37713598 http://dx.doi.org/10.1093/stcltm/szad051 |
Ejemplares similares
-
Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical results
por: ÖZMERT, Emin, et al.
Publicado: (2020) -
Management of retinitis pigmentosa by Wharton’s jelly-derived mesenchymal stem cells: prospective analysis of 1-year results
por: Özmert, Emin, et al.
Publicado: (2020) -
Management of toxic optic neuropathy via a combination of Wharton’s jelly-derived mesenchymal stem cells with electromagnetic stimulation
por: Özmert, Emin, et al.
Publicado: (2021) -
Wharton's jelly mesenchymal stem cells differentiate into retinal progenitor cells
por: Hu, Ying, et al.
Publicado: (2013) -
Safety and efficacy of Wharton's jelly‐derived mesenchymal stem cells with teriparatide for osteoporotic vertebral fractures: A phase I/IIa study
por: Shim, JeongHyun, et al.
Publicado: (2020)